Residual HCV Transmission among People with HIV: Longitudinal Trends in Prevalence and Incidence of HCV Viremia, and Reinfection After Universal Coverage of Direct-Acting Antivirals in Taiwan (2019–2025)

During 2017–2025, Taiwan had made substantial progress toward HCV elimination with achievement of 92.6% direct-acting antiviral coverage. In this setting, monitoring the residual transmissions of HCV among high-risk populations become essential. Therefore, we conducted this cohort study to evaluate the temporal trends in HCV infection among people with HIV (PWH). PWH who regularly sought HIV care at the National Taiwan University Hospital were included for periodical HCV antibody screening, and HCV-seropositive PWH underwent HCV RNA testing. PWH who cleared HCV viremia, by treatment or spontaneously, were followed using HCV RNA tests to detect reinfections. The prevalence and incidence of HCV viremia and incidence of reinfection were calculated yearly from 2019–2025. The estimates in 2025 were compared to the peak estimates of the cohort. Overall, 3,637 PWH, with a median age of 40.4 years and 81.4% being men who have sex with men, were included in the study. Compared to 2019, the prevalence of HCV viremia decreased from 4.4% to 0.9% in 2025, representing a 78.7% reduction (95% CI, 66.9%–86.2%); and the incidence decreased from 25.9 to 7.4 per 1,000 person-years in 2025, corresponding to a 70.9% reduction (95% CI, 51.9%–82.4%). Temporal analysis demonstrated significant declines of HCV viremia incidence in 2019–2022, followed by a plateau phase in 2023–2025. Our finding supported that nationwide progress toward HCV elimination has contributed to the significant reduction of HCV burden among PWH; however, the plateau phase indicates potential ongoing, residual HCV transmission among PWH with continued risk behaviors.

Authors

Publication Details

Journal
Figshare
Published
2026-11-16
DOI
https://doi.org/10.6084/m9.figshare.35024527
Primary Topic
Hepatitis C virus research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Residual HCV Transmission among People with HIV: Longitudinal Trends in Prevalence and Incidence of HCV Viremia, and Reinfection After Universal Coverage of Direct-Acting Antivirals in Taiwan (2019–2025)

Ling-Ya Chen, Hsi‐Yen Chang, Wang-Da Liu, Kuan-Yin Lin et al.
4 links
Figshare
Hepatitis C virus research
article

Residual HCV Transmission among People with HIV: Longitudinal Trends in Prevalence and Incidence of HCV Viremia, and Reinfection After Universal Coverage of Direct-Acting Antivirals in Taiwan (2019–2025)

Ling-Ya Chen, Hsi‐Yen Chang, Wang-Da Liu, Kuan-Yin Lin, Wen Chen, Yu‐Zhen Luo, Chien-Ching Hung, Yu-Shan Huang, Guan-Jhou Chen, Yi-Ching Su, Aristine Cheng, Yu-Chung Chuang, Li-Hsin Su, Hsin-Yun Sun, Wen-Chun Liu, Pei-Ying Wu, Yi-Ting Chen, Yi-Chia Huang
article en

Abstract

During 2017–2025, Taiwan had made substantial progress toward HCV elimination with achievement of 92.6% direct-acting antiviral coverage. In this setting, monitoring the residual transmissions of HCV among high-risk populations become essential. Therefore, we conducted this cohort study to evaluate the temporal trends in HCV infection among people with HIV (PWH). PWH who regularly sought HIV care at the National Taiwan University Hospital were included for periodical HCV antibody screening, and HCV-seropositive PWH underwent HCV RNA testing. PWH who cleared HCV viremia, by treatment or spontaneously, were followed using HCV RNA tests to detect reinfections. The prevalence and incidence of HCV viremia and incidence of reinfection were calculated yearly from 2019–2025. The estimates in 2025 were compared to the peak estimates of the cohort. Overall, 3,637 PWH, with a median age of 40.4 years and 81.4% being men who have sex with men, were included in the study. Compared to 2019, the prevalence of HCV viremia decreased from 4.4% to 0.9% in 2025, representing a 78.7% reduction (95% CI, 66.9%–86.2%); and the incidence decreased from 25.9 to 7.4 per 1,000 person-years in 2025, corresponding to a 70.9% reduction (95% CI, 51.9%–82.4%). Temporal analysis demonstrated significant declines of HCV viremia incidence in 2019–2022, followed by a plateau phase in 2023–2025. Our finding supported that nationwide progress toward HCV elimination has contributed to the significant reduction of HCV burden among PWH; however, the plateau phase indicates potential ongoing, residual HCV transmission among PWH with continued risk behaviors.

Figshare
Good health and well-being
Hepatitis C virus research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon